Janux Therapeutics Appoints Brenda Van Vreeswyk as Head of Human Resources
SAN DIEGO--(BUSINESS WIRE)-- Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced the appointment of Brenda Van Vreeswyk as Head of Human Resources (HR). Ms. Van Vreeswyk brings extensive HR leadership and operations expertise across the life sciences industry, including biopharma, diagnostics, and medical device companies, and most recently served as Director, HR for Neurocrine Biosciences.
“We are excited to welcome Brenda to Janux as we continue making progress across our pipeline and evolve as a clinical-stage company,” said David Campbell, Ph.D., President and CEO of Janux. “Her track record at Neurocrine of delivering human resources strategies to enable high-performing clinical, supply-chain, and commercial teams globally will be instrumental as we continue to grow as a biotech company, advance our pipeline, and build development capabilities that will be essential to our future growth. Brenda has the experience of operating at scale in a science-driven company and will be a great partner to ensure we maintain the uniqueness of our culture.”
“I am thrilled to be joining the Janux team at such an important time as the company moves its unique science and technology forward into the clinic. I have spent time with the talented leaders at the company, and I am thoroughly impressed by the sophistication, pace, and breadth of the organization,” said Ms. Van Vreeswyk. “I look forward to building upon the good work done to date and continuing to advance the company’s organizational and talent strategies to ensure we are best positioned as we grow to have the highest impact on cancer patients.”
Ms. Van Vreeswyk’s contributions in HR include recruitment of science, clinical and commercial talent, developing leadership training programs, and employee engagement initiatives. At Neurocrine, she was responsible for developing and implementing talent capability strategies for its commercial, clinical, and supply chain teams. She also served as a member of Neurocrine’s HR Executive Team which guided the HR strategy supporting the expansion of Neurocrine to a leading commercial biopharma company. Ms. Van Vreeswyk earned her B.S. in organizational behavior from the University of San Francisco. She is a member of the Society of Human Resources and has served in leadership roles at various HR associations.
About Janux Therapeutics
Janux Therapeutics is an innovative biopharmaceutical company developing next-generation therapeutics based on applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms to better treat patients suffering from cancer. Janux’s initial focus is on developing a novel class of T cell engagers (TCEs), and its lead product candidates are designed to target clinically validated drug targets. While TCE therapeutics have displayed potent anti-tumor activity in hematological cancers, developing TCEs to treat solid tumors have faced challenges due to the limitations of prior TCE technologies, namely (i) overactivation of the immune system leading to cytokine release syndrome, (ii) on-target, healthy tissue toxicities, and (iii) poor pharmacokinetics leading to short half-life. Janux is using its TRACTr platform technology to engineer product candidates designed to overcome these limitations by offering accuracy, stability, activity, modularity, and manufacturability. Janux is developing a broad pipeline with lead TRACTr programs targeting prostate-specific membrane antigen (PSMA), epidermal growth factor receptor (EGFR), and trophoblast cell surface antigen 2 (TROP2). Janux is also applying its proprietary technology to develop a TRACIr costimulatory bispecific product candidate against programmed death-ligand 1 (PD-L1) and Cluster of Differentiation 28 (CD28) designed to further enhance the anti-tumor activity of T cells. For more information, please visit www.januxrx.com.
This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, Janux’s ability to bring new treatments to cancer patients in need and the progress and expected timing of Janux’s drug development programs. Factors that may cause actual results to differ materially include the risk that compounds that appear promising in early research do not demonstrate safety and/or efficacy in later preclinical studies or clinical trials, the risk that Janux may not obtain approval to market its product candidates, uncertainties associated with performing clinical trials, regulatory filings and applications, risks associated with reliance on third parties to successfully conduct clinical trials, the risks associated with reliance on outside financing to meet capital requirements, and other risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. You are urged to consider statements that include the words “may,” “will,” “would,” “could,” “should,” “believes,” “estimates,” “projects,” “promise,” “potential,” “expects,” “plans,” “anticipates,” “intends,” “continues,” “designed,” “goal,” or the negative of those words or other comparable words to be uncertain and forward-looking. For a further list and description of the risks and uncertainties Janux faces, please refer to Janux’s periodic and other filings with the Securities and Exchange Commission, which are available at www.sec.gov. Such forward-looking statements are current only as of the date they are made, and Janux assumes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220923005057/en/
Jessica Yingling, Ph.D.
Little Dog Communications Inc.
Source: Janux Therapeutics, Inc.
View this news release online at: